Marco Meglio, Assistant Managing Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at mmeglio@neurologylive.com
Maitland’s Joint Mobilization Therapy Proves Beneficial for Systemic Sclerosis
September 9th 2021Every patient who underwent physical therapy reported a positive change, ranging from moderately better to much better, while 9 patients on placebo did not notice significant changes or reported worsening of their condition.
NeuroVoices: Paul G. Mathew, MD, on Educating Clinical Community on Nerve Block Surgery Benefits
September 8th 2021The assistant professor of neurology at Harvard Medical School provided insight on how to improve care for posttraumatic headache, as well as limitations and benefits to nerve block surgeries.
ADVANCE Study Results Demonstrate Atogepant’s Potential for Migraine Prevention
August 24th 2021For the primary end point, the 3 dose options atogepant (AbbVie) were associated with a reduction ranging from 3.9 to 4.2 days in the mean number of headache days per month for those with episodic migraine.
BTK Inhibitor Fenebrutinib Aims to Tackle Progressive MS in FENtrepid Trial
August 20th 2021The agent’s safety profile has been studied in more than 1200 individuals to date across several inflammatory diseases, with data indicating that the high selectivity of fenebrutinib may limit off-target effects.
Associations Between Contrast-Enhancing Lesions and MS Disease Spectrums Raise Questions
August 18th 2021Multivariable logistic regression models found age to be the only characteristic associated with the risk of CELs at baseline in all datasets, with a higher age associated with a lower risk of CELs.
NeuroVoices: James Galvin, MD, MPH, on Location and Greenhouse Space Effects on Alzheimer Risk
August 18th 2021The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine provided context on greenhouse spaces and their preventive benefits in Alzheimer disease.